ReviewAdvances in chronic kidney disease2020
Management of Acute Kidney Injury in Coronavirus Disease 2019.
Review in Advances in chronic kidney disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Mortality Rate and Its Contributing Factors in Post-Surgical and Medical Patients with AKI Underwent CRRT.Tanaffos · 2024Article
- Impact of the COVID-19 pandemic on services for patients with chronic kidney disease: findings of a national survey of UK kidney centres.BMC nephrology · 2023Article
- Overview of acute kidney manifestations and management of patients with COVID-19.American journal of physiology. Renal physiology · 2021Review
- COVID-19 impact on the renal system: Pathophysiology and clinical outcomes.Best practice & research. Clinical anaesthesiology · 2021Review
- Clinical Scoring for Prediction of Acute Kidney Injury in Patients with Acute ST-Segment Elevation Myocardial Infarction after Emergency Primary Percutaneous Coronary Intervention.Journal of clinical medicine · 2021Article
- Gastrointestinal and renal complications in SARS-CoV-2-infected patients: Role of immune system.Scandinavian journal of immunology · 2021Review
- COVID-19 and the Kidney: A Worrisome Scenario of Acute and Chronic Consequences.Journal of clinical medicine · 2021Review
- Questionnaire Survey on the Current Situation and Experience in Prevention and Control Measures at Urology Clinics During the COVID-19 Epidemic in China.Frontiers in public health · 2021Article
- Pathophysiology and Pathology of Acute Kidney Injury in Patients With COVID-19.Advances in chronic kidney disease · 2020Review
- Can GPR4 Be a Potential Therapeutic Target for COVID-19?Frontiers in medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute kidney injury is a common complication in hospitalized patients with coronavirus disease 2019. Similar to acute kidney injury associated with other conditions such as sepsis and cardiac surgery, morbidity and mortality are much higher in patients with coronavirus disease 2019 who develop acute kidney injury, especially in the intensive care unit. Management of coronavirus disease 2019-associated acute kidney injury with kidney replacement therapy should follow existing recommendations regarding modality, dose, and timing of initiation. However, patients with coronavirus disease 2019 are very hypercoagulable, and close vigilance to anticoagulation strategies is necessary to prevent circuit clotting. During situations of acute surge, where demand for kidney replacement therapy outweighs supplies, conservative measures have to be implemented to safely delay kidney replacement therapy. A collaborative effort and careful planning is needed to conserve dialysis supplies, to ensure that treatment can be safely delivered to every patient who will benefit for kidney replacement therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.